Elicea Use In Pregnancy & Lactation

Pregnancy: For escitalopram only limited clinical data are available regarding exposed pregnancies.
Escitalopram should not be used during pregnancy unless clearly needed and only after careful consideration of the risk/benefit ratio.
Newborns should be observed if maternal use of escitalopram continues into the later stages of pregnancy, particularly in the third trimester. If escitalopram is used until or shortly before birth, discontinuation effects in the newborn are possible.
The following symptoms may occur in the neonate after maternal SSRI/SNRI use in later stages of pregnancy: respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying, somnolence and difficulty sleeping. These symptoms could be due to either serotonergic effects or discontinuation symptoms. In a majority of instances the complications begin immediately or soon (<24 hours) after delivery.
Lactation: It is expected that escitalopram will be excreted into human milk and breast-feeding is not recommended during treatment.
Fertility: Impact on human fertility has not been observed so far.